Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · IEX Real-Time Price · USD
33.88
+0.59 (1.77%)
At close: Jul 19, 2024, 4:00 PM
33.93
+0.05 (0.15%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $523.53M in the twelve months ending March 31, 2024, with 26.51% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $146.81M with 38.95% year-over-year growth. In the year 2023, Corcept Therapeutics had annual revenue of $482.38M with 20.04% growth.
Revenue (ttm)
$523.53M
Revenue Growth
+26.51%
P/S Ratio
6.74
Revenue / Employee
$1,487,298
Employees
352
Market Cap
3.53B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
Dec 31, 2012 | 3.31M | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
Dec 31, 2006 | 294.00K | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Dec 31, 2001 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amedisys | 2.25B |
Prestige Consumer Healthcare | 1.13B |
Neogen | 929.24M |
HUTCHMED (China) | 838.00M |
Axonics | 387.14M |
TG Therapeutics | 289.33M |
PROCEPT BioRobotics | 156.33M |
Arcellx | 131.66M |
CORT News
- 4 days ago - These small-cap stocks score highest when screened for quality - Market Watch
- 27 days ago - Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions - GlobeNewsWire
- 7 weeks ago - Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome) - GlobeNewsWire
- 2 months ago - Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement - Accesswire
- 2 months ago - Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewsWire
- 4 months ago - Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome - GlobeNewsWire
- 5 months ago - Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update - GlobeNewsWire